A Phase 3 interventional study of Rituximab and Doxorubicin in Diffuse Large B-Cell Lymphoma, sponsored by Mabion SA. Completed at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.
Sponsored by Mabion SA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.
Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 33rd largest by enrollment of the 211 interventional ones that give a count, is one of 6 that started in 2015, is one of 30 in phase 3, and was the 145th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 65+
Paolo Caimi, MD · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Ou Bai, MD/PHD · Sites in China
Ages 70+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 60+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
218 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 146 · Phase 3 32 · Phase 4 3
First in 1993; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 46 across the 211 interventional studies. Of the 142 that completed or were terminated, 61 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 218 have an industry lead sponsor. The 10 most frequent:
Mabion SA is the lead sponsor of 3 studies on the registry; none are open to participants now.
Mabion SA has 1 study filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
7 of the studies testing rituximab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06573645Phase 3Xia YiA Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | 2027-01-12 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT04978584M.D. Anderson Cancer CenterRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | 2027-01-16 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20 (MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients with CD20-positive diffuse large B-cell lymphoma.
Patients who meet criteria for participation in this study receive 8 intravenous infusions of MabionCD20® or MabThera® 21 days interval in combination with standard dosage regimen of CHOP. The duration of the study is 12 months. The treatment and observation period will last 26 weeks starting from Day 1, until Week 26 - one month after last IMP infusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A course of MabionCD20 consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles. Intervention: Drug: Rituximab
Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: prednisone
A course of MabThera consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles. Intervention: Drug: Rituximab
Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: prednisone
375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
Also known as: MabThera®, MabionCD20®
50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
Also known as: Hydroxydaunorubicin
1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
Also known as: Oncovine
750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])
Area under the serum concentration-time curve from time zero (Day 1) to final time point measured after the first administration (Week 1) until Week 4 (AUC(W1-W4)). PK blood samples for this endpoint were drawn at Day 1 (before and after the first infusion), Day 8 ± 1 (7 days after first infusion), Day 15 ± 1 (14 days after first infusion), Day 22 ± 2 (before and after completion of the second infusion).
Time frame: Baseline to Week 4
Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])
Area under the serum concentration-time curve from time zero to final time point measured from Week 13 until Week 26 (AUC\[W13-W26\]). PK blood samples for this endpoint were drawn at Day 85 ± 4 (before and after completion of the fifth infusion), Day 106 ± 4 (before and after completion of sixth infusion), Day 127 ± 4 (before and after completion of the seventh infusion), Day 148 ± 4 (before and after completion of the eight infusion), Day 155 ± 4 (one week after last infusion) and Day 176 ± 4 (one month after last infusion).
Time frame: Week 13 to Week 26
Ctrough (Before 8th Infusion)
Trough serum concentration measured at the end of a dosing interval at steady state, taken directly before eighth infusion.
Time frame: Week 22
Cmax (Post 5th and 8th Infusion)
Maximum serum drug concentration (Cmax) at steady state after the 5th and 8th infusions.
Time frame: Week 13 (5th infusion) and Week 22 (8th infusion)
Kel (Post 5th and 8th Infusions)
Elimination Rate Constant at steady stade after the 5th and 8th infusions.
Time frame: Week 13 (5th infusion) and Week 22 (8th infusion)
T1/2 (Post 5th and 8th Infusions)
Elimination half-life at steady state after the 5th and 8th infusions.
Time frame: Week 13 to Week 16 and Week 22 to Week 26
CLss (Post 5th and 8th Infusions)
Clearance at steady state after the 5th and 8th infusions.
Time frame: Week 13 to Week 16 and Week 22 to Week 26
AUC (W1-W26) B-cell
Area under the serum concentration-time curve of CD19+ B cell counts, measured from the first administration to the final time point at Week 26 (AUC(1-26) B-cell).
Time frame: baseline to Week 26
AUC (W1-W26)
Area under the serum concentration-time curve measured after the first administration (Week 1) until Week 26 (AUC(1-26))
Time frame: Week 1 until Week 26
Efficacy Assessment at Week 26
An efficacy assessment was made after 8 treatment cycles (at Week 26) based on tumour responses classified according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (Cheson et al. 1999). Response was assessed based on clinical, radiologic (CT scan) and pathologic (bone marrow) criteria. Possible efficacy responses were: complete response, partial response, stable disease, and progressive disease. Efficacy reported here includes all patients included in the ITT set.
Time frame: Week 26
Adverse Events
Percentage of patients with at least one AE in a given category. Data from the entire follow-up are included (Period 1 and Period 2).
Time frame: from baseline to Week 46
Immunogenicity
Percentage of patients with positive ADA or NAb results in a given category. Data pertain to the entire follow-up period (from Baseline to Week 46).
Time frame: from baseline to Week 46
The trial was initiated in 7 countries (Croatia, Bosnia and Herzegovina, Georgia, Moldova, Poland, Serbia, and Ukraine), but finally only 5 countries with 21 study sites recruited patients (Bosnia and Herzegovina, Georgia, Moldova, Poland, and Ukraine). Start date of recruitment: 29.03.2016
| Milestone | MabionCD20 | MabThera |
|---|---|---|
| Started | 100 | 40 |
| Completed | 85 | 35 |
| Not completed | 15 | 5 |
| Withdrew: Adverse event | 9 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Patient needed radiotherapy | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | MabionCD20 | MabThera |
|---|---|---|
| Started | 85 | 35 |
| Completed | 70 | 29 |
| Not completed | 15 | 6 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Disease progression | 2 | 1 |
| Withdrew: Need for cns prophylaxis | 1 | 0 |
| Withdrew: Patient needed radiotherapy | 9 | 5 |
| Withdrew: Patient needed bone marrow transplantation | 1 | 0 |
Area under the serum concentration-time curve from time zero (Day 1) to final time point measured after the first administration (Week 1) until Week 4 (AUC(W1-W4)). PK blood samples for this endpoint were drawn at Day 1 (before and after the first infusion), Day 8 ± 1 (7 days after first infusion), Day 15 ± 1 (14 days after first infusion), Day 22 ± 2 (before and after completion of the second infusion).
| (μg*day)/mL | MabionCD20 | MabThera |
|---|---|---|
| Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4]) | 1559.51 ± 358.092 | 1509.79 ± 382.559 |
Area under the serum concentration-time curve from time zero to final time point measured from Week 13 until Week 26 (AUC\[W13-W26\]). PK blood samples for this endpoint were drawn at Day 85 ± 4 (before and after completion of the fifth infusion), Day 106 ± 4 (before and after completion of sixth infusion), Day 127 ± 4 (before and after completion of the seventh infusion), Day 148 ± 4 (before and after completion of the eight infusion), Day 155 ± 4 (one week after last infusion) and Day 176 ± 4 (one month after last infusion).
| (μg*day)/mL | MabionCD20 | MabThera |
|---|---|---|
| Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26]) | 16498.9 ± 3492.39 | 15647.4 ± 3629.83 |
Trough serum concentration measured at the end of a dosing interval at steady state, taken directly before eighth infusion.
| μg/mL | MabionCD20 | MabThera |
|---|---|---|
| Ctrough (Before 8th Infusion) | 102.246 ± 43.897 | 90.61 ± 41.994 |
Maximum serum drug concentration (Cmax) at steady state after the 5th and 8th infusions.
| μg/mL | MabionCD20 | MabThera |
|---|---|---|
| 5th infusion | 273.356 ± 65.452 | 266.439 ± 66.086 |
| 8th infusion | 296.784 ± 58.295 | 296.462 ± 69.641 |
Elimination Rate Constant at steady stade after the 5th and 8th infusions.
| 1/day | MabionCD20 | MabThera |
|---|---|---|
| 5th infusion | 0.05663 ± 0.01794 | 0.05418 ± 0.01884 |
| 8th infusion | 0.04335 ± 0.01528 | 0.04379 ± 0.0123 |
Elimination half-life at steady state after the 5th and 8th infusions.
| days | MabionCD20 | MabThera |
|---|---|---|
| 5th infusion | 14.801 ± 12.218 | 15.217 ± 7.889 |
| 8th infusion | 18.301 ± 7.92 | 16.997 ± 4.515 |
Clearance at steady state after the 5th and 8th infusions.
| mL/day | MabionCD20 | MabThera |
|---|---|---|
| 5th infusion | 198.701 ± 53.427 | 206.905 ± 78.213 |
| 8th infusion | 179.168 ± 58.509 | 191.272 ± 89.016 |
Area under the serum concentration-time curve of CD19+ B cell counts, measured from the first administration to the final time point at Week 26 (AUC(1-26) B-cell).
| cells*days/mL blood | MabionCD20 | MabThera |
|---|---|---|
| AUC (W1-W26) B-cell | 3395.82 ± 22364.5 | 10476.2 ± 56943.0 |
Area under the serum concentration-time curve measured after the first administration (Week 1) until Week 26 (AUC(1-26))
| (μg*day)/mL | MabionCD20 | MabThera |
|---|---|---|
| AUC (W1-W26) | 28413.6 ± 5194.98 | 26955.3 ± 5849.22 |
An efficacy assessment was made after 8 treatment cycles (at Week 26) based on tumour responses classified according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (Cheson et al. 1999). Response was assessed based on clinical, radiologic (CT scan) and pathologic (bone marrow) criteria. Possible efficacy responses were: complete response, partial response, stable disease, and progressive disease. Efficacy reported here includes all patients included in the ITT set.
| Participants | MabionCD20 | MabThera |
|---|---|---|
| Complete | 34 | 14 |
| Partial | 42 | 18 |
| Stable disease | 10 | 4 |
| Progressive disease | 10 | 2 |
| Missing | 4 | 2 |
Percentage of patients with at least one AE in a given category. Data from the entire follow-up are included (Period 1 and Period 2).
| percent | MabionCD20 | MabThera |
|---|---|---|
| all AEs | 71.0 | 67.5 |
| TEAEs | 71.0 | 65.0 |
| TESAEs | 19.0 | 12.5 |
| severe TEAEs | 40.0 | 22.5 |
| related TEAEs | 53.0 | 42.5 |
| related severe TEAEs | 29.0 | 22.5 |
| related TESAEs | 13.0 | 5.0 |
| TEAEs leading to death | 8.0 | 0 |
| related TEAEs leading to death | 2.0 | 0 |
Percentage of patients with positive ADA or NAb results in a given category. Data pertain to the entire follow-up period (from Baseline to Week 46).
| participants | MabionCD20 | MabThera |
|---|---|---|
| Treatment-induced ADA | 6 | 1 |
| Persistent ADA | 4 | 1 |
| Transient ADA | 2 | 0 |
| Treatment-boosted ADA | 0 | 0 |
| NAb positive | 0 | 0 |
Collected over 46 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MabionCD20 | 8/100 (8%) | 19/100 (19%) | 70/100 (70%) |
| MabThera | 0/40 (0%) | 5/40 (12.5%) | 26/40 (65%) |
| Event | MabionCD20 | MabThera |
|---|---|---|
| PneumoniaInfections and infestations | 3/100 | 0/40 |
| Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/100 | 0/40 |
| AnaemiaBlood and lymphatic system disorders | 1/100 | 1/40 |
| Disease progressionGeneral disorders | 0/100 | 1/40 |
| SepsisInfections and infestations | 0/100 | 1/40 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/100 | 1/40 |
| Haemorrhagic strokeNervous system disorders | 0/100 | 1/40 |
| Cardiac failureCardiac disorders | 2/100 | 0/40 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/100 | 0/40 |
| HypotensionVascular disorders | 2/100 | 0/40 |
| Event | MabionCD20 | MabThera |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 29/100 | 10/40 |
| LeukopeniaBlood and lymphatic system disorders | 22/100 | 10/40 |
| AlopeciaSkin and subcutaneous tissue disorders | 15/100 | 5/40 |
| AnaemiaBlood and lymphatic system disorders | 14/100 | 5/40 |
| Neutrophil count decreasedInvestigations | 8/100 | 4/40 |
| White blood count decreasedInvestigations | 9/100 | 4/40 |
| DiarrhoeaGastrointestinal disorders | 3/100 | 3/40 |
| Respiratory tract infectionInfections and infestations | 7/100 | 1/40 |
| StomatitisGastrointestinal disorders | 3/100 | 2/40 |
| FatigueGeneral disorders | 5/100 | 1/40 |
SAF (all patients randomized into the study and receiving at least one infusion of MabionCD20 or MabThera).
| Age, Categorical(Participants) | MabionCD20 | MabThera | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 78 | 29 | 107 |
| >=65 years | 22 | 11 | 33 |
| Age, Continuous(years) | MabionCD20 | MabThera | Total |
|---|---|---|---|
| Mean | 51.5 ± 16.2 | 54.3 ± 13.5 | 52.3 ± 15.5 |
| Sex: Female, Male(Participants) | MabionCD20 | MabThera | Total |
|---|---|---|---|
| Female | 54 | 20 | 74 |
| Male | 46 | 20 | 66 |
| Race (NIH/OMB)(Participants) | MabionCD20 | MabThera | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 100 | 40 | 140 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| BSA(cubic metre) | MabionCD20 | MabThera | Total |
|---|---|---|---|
| Mean | 1.9 ± 0.2 | 1.8 ± 0.2 | 1.8 ± 0.2 |
| Body weight(kilograms) | MabionCD20 | MabThera | Total |
|---|---|---|---|
| Mean | 76.2 ± 17.4 | 73.6 ± 17 | 75.5 ± 17.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Aug 2017, 20 months.
Results were first posted in Oct 2023, 6 years 2 months after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 20 months is below that.
Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Lymphoma, Large B-Cell, Diffuse →